Press Releases

InVivo Therapeutics Reports First Quarter 2013 Financial Results, Provides Business Update

Published: May 9, 2013

CAMBRIDGE, Mass. (May 9, 2013) – InVivo Therapeutics Holdings Corp. (NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI) and other neurotrauma conditions, today reported financial results for the three months ended March 31, 2013 and provided a business update. InVivo has pioneered a new treatment platform utilizing a variety of biocompatible polymer-based devices to provide structural support to a damaged spinal cord in order to spare tissue from scarring while improving functional recovery and prognosis after a traumatic spinal cord injury. Today there is no effective treatment for the spinal cord for paralysis caused […]

View Article
InVivo Therapeutics Named a 2013 “Best Places to Work” Winner by Boston Business Journal

Published: May 2, 2013

CAMBRIDGE, Mass. (May 2, 2013) – InVivo Therapeutics Holdings Corp. (NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI) and other neurotrauma conditions, today announced that the Company has been named one of the Best Places to Work in Massachusetts by the The Boston Business Journal in its eleventh annual regional awards program. The honor recognizes the Company’s achievements in creating a positive work environment that attracts and retains employees through a combination of employee satisfaction, working conditions and company culture. InVivo Therapeutics was one of over 400 companies to qualify for consideration based on […]

View Article
InVivo Enters Commercialization Phase, Adds John A. McCarthy to Board of Directors

Published: April 23, 2013

CAMBRIDGE, Mass. (April 23, 2013) – InVivo Therapeutics Holdings Corp. (NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI) and other neurotrauma conditions, today announced that John A. McCarthy, Chief Executive Officer at CryoXtract, has joined InVivo’s Board of Directors. McCarthy has also been appointed as Chair of the Board’s Audit committee, and has become a member of the Governance, Nominating and Compensation committee. “We’ve turned the corner on development and we’re full steam ahead on commercialization for multiple products. We expect that two 510(k) neurological devices will enter the market by the end 2014. […]

View Article
InVivo Therapeutics Announces Warrant Exchange Offer with Intent to Up-List to a National Securities Exchange

Published: April 8, 2013

CAMBRIDGE, Mass. (April 8, 2013) – InVivo Therapeutics Holdings Corp. (NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI) and other neurotrauma conditions, today announced that it has commenced an offer to exchange outstanding warrants issued in 2010 to purchase approximately 15.0 million common shares (“2010 warrants”) for new warrants. The 2010 warrants have exercise prices of $1.40 and $1.00 per share and expire in 2015. One of the primary reasons for the offering is to facilitate the Company’s plans to uplist its stock to a national securities exchange such as NASDAQ or NYSE MKT. […]

View Article
InVivo Therapeutics Receives Approval from FDA for First Human Trial Using Biomaterials for Traumatic Spinal Cord Injury

Published: April 5, 2013

CAMBRIDGE, Mass. (April 5, 2013) – InVivo Therapeutics Holdings Corp. (NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI) and other neurotrauma conditions, today announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s Investigational Device Exemption (IDE) to begin human studies to test its biopolymer scaffold product, a technology developed to treat patients with acute, traumatic SCI. With this approval, InVivo intends to commence a first-in-man clinical study in the next few months that will test safety and performance of its biopolymer scaffold in five patients. The Company expects the study […]

View Article
InVivo Therapeutics Receives Humanitarian Use Device Designation for Spinal Cord Injury Treatment

Published: April 4, 2013

CAMBRIDGE, Mass. (April 4, 2013) – InVivo Therapeutics Holdings Corp. (NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI) and other neurotrauma conditions, today announced that the Company has received approval for its request filed with the U.S. Food and Drug Administration (FDA) for Humanitarian Use Device (HUD) designation for its biopolymer scaffolding product. HUD designation covers devices that treat rare, ‘orphan’ diseases or conditions. InVivo has received designation for the use of its biopolymer scaffolding for the treatment of recent complete spinal cord injury (no motor or sensory function) that does not involve penetrating […]

View Article
InVivo Therapeutics Sponsors 2013 RISE Above Paralysis Gala

Published: March 14, 2013

CAMBRIDGE, Mass. (March 14, 2013) – InVivo Therapeutics Holdings Corp. (NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI) and other neurotrauma conditions, today announced that the Company has renewed its support for the Greater Boston Chapter of the National Spinal Cord Injury Association (NSCIA), a non-profit organization that offers programs and services to those with spinal cord injury and disease. InVivo will serve as a Premier sponsor at the RISE Above Paralysis Gala this Saturday, March 16, 2013, an annual event hosted by the Greater Boston Chapter of the NSCIA. The evening will bring […]

View Article
InVivo Therapeutics Reports 2012 Financial Results, Provides Business Update

Published: March 13, 2013

CAMBRIDGE, Mass. (March 13, 2013) – InVivo Therapeutics Holdings Corp. (OTC/BB: NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI) and other neurotrauma conditions, today reported financial results for the year ended December 31, 2012 and provided a business update. InVivo has pioneered a new treatment platform utilizing a variety of biocompatible polymer-based devices to provide structural support to a damaged spinal cord in order to spare tissue from scarring while improving functional recovery and prognosis after a traumatic SCI. Today there is no effective treatment for the spinal cord for paralysis caused by SCIs, […]

View Article
InVivo Therapeutics Submits Updated IDE to FDA to Begin Spinal Cord Injury Human Study

Published: February 28, 2013

CAMBRIDGE, Mass. (February 28, 2013) – InVivo Therapeutics Holdings Corp. (NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI) and other neurotrauma conditions, today announced the Company has submitted an updated Investigational Device Exemption (IDE) to the U.S. Food and Drug Administration (FDA) requesting permission to begin human studies in order to test its biopolymer scaffolding for the treatment of acute SCI. The updated IDE submission is in response to exchanges since InVivo’s April 12, 2012 meeting with the FDA. The filing contains additional information regarding the manufacturing and pre-clinical testing of the scaffolding device. […]

View Article
InVivo Therapeutics Calls for Papers for 2nd Annual Langer Summit on Neurotrauma

Published: February 7, 2013

CAMBRIDGE, Mass. (February 7, 2013) – InVivo Therapeutics Holdings Corp. (NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI) and other neurotrauma conditions, today announced the 2nd Annual Langer Summit on Neurotrauma, taking place on Cape Cod in North Falmouth, MA on July 12 – 14, 2013. The Company is inviting papers in the fields of neurotrauma and SCI, and will announce the recipient of a $50,000 grant that will be given to a researcher developing novel biomaterial treatments for neurotrauma at the Summit. The award is intended to stimulate innovation and cutting-edge ideas in […]

View Article

The information in the press releases on these pages was factually accurate on the date of publication. These press releases remain on the InVivo website for historical purposes only. InVivo assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon the information in these pages as current or accurate after their publication dates.